 Brandon Mcmahon
Concepts (245)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thrombosis | 5 | 2015 | 348 | 1.300 |
Why?
| | Myeloproliferative Disorders | 8 | 2022 | 26 | 1.280 |
Why?
| | Urokinase-Type Plasminogen Activator | 4 | 2015 | 29 | 1.030 |
Why?
| | Plasminogen Activator Inhibitor 1 | 3 | 2015 | 84 | 0.930 |
Why?
| | Thrombocytopenia | 3 | 2016 | 189 | 0.900 |
Why?
| | Neoplasms | 8 | 2020 | 2450 | 0.840 |
Why?
| | Hemorrhage | 5 | 2018 | 680 | 0.840 |
Why?
| | Anticoagulants | 4 | 2018 | 637 | 0.820 |
Why?
| | Plasminogen | 3 | 2013 | 30 | 0.730 |
Why?
| | Fibrinolysin | 2 | 2013 | 17 | 0.710 |
Why?
| | Receptors, Urokinase Plasminogen Activator | 2 | 2015 | 15 | 0.550 |
Why?
| | Liver Cirrhosis | 2 | 2020 | 281 | 0.530 |
Why?
| | Anemia, Pernicious | 1 | 2016 | 9 | 0.520 |
Why?
| | Pancytopenia | 1 | 2016 | 8 | 0.510 |
Why?
| | Hypothyroidism | 1 | 2016 | 66 | 0.490 |
Why?
| | Neoplasm Proteins | 2 | 2009 | 417 | 0.490 |
Why?
| | Myelodysplastic Syndromes | 2 | 2016 | 129 | 0.470 |
Why?
| | Unnecessary Procedures | 1 | 2014 | 48 | 0.440 |
Why?
| | Tissue Inhibitor of Metalloproteinase-2 | 1 | 2013 | 15 | 0.410 |
Why?
| | Heparin | 1 | 2014 | 253 | 0.400 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 836 | 0.380 |
Why?
| | Thrombophilia | 2 | 2009 | 81 | 0.370 |
Why?
| | Polycythemia Vera | 4 | 2022 | 12 | 0.360 |
Why?
| | Blood Platelets | 1 | 2014 | 386 | 0.350 |
Why?
| | Fibrinolysis | 2 | 2009 | 137 | 0.350 |
Why?
| | Medical Oncology | 4 | 2022 | 267 | 0.320 |
Why?
| | Biomarkers, Tumor | 2 | 2018 | 1159 | 0.310 |
Why?
| | Interferon Type I | 3 | 2015 | 139 | 0.300 |
Why?
| | Tissue Plasminogen Activator | 2 | 2009 | 222 | 0.290 |
Why?
| | Antineoplastic Agents | 5 | 2018 | 2044 | 0.280 |
Why?
| | Intracellular Signaling Peptides and Proteins | 3 | 2015 | 443 | 0.260 |
Why?
| | Primary Myelofibrosis | 2 | 2022 | 9 | 0.230 |
Why?
| | Fetomaternal Transfusion | 1 | 2023 | 11 | 0.210 |
Why?
| | Thrombocythemia, Essential | 1 | 2022 | 7 | 0.200 |
Why?
| | Interferon-alpha | 2 | 2014 | 194 | 0.200 |
Why?
| | Humans | 34 | 2023 | 129527 | 0.190 |
Why?
| | Telomerase | 2 | 2020 | 230 | 0.190 |
Why?
| | MAP Kinase Signaling System | 2 | 2015 | 312 | 0.190 |
Why?
| | Graft vs Host Disease | 1 | 2023 | 240 | 0.180 |
Why?
| | Mutation | 4 | 2020 | 3702 | 0.150 |
Why?
| | Mastocytosis, Systemic | 1 | 2018 | 8 | 0.150 |
Why?
| | Pregnancy Complications | 1 | 2023 | 493 | 0.150 |
Why?
| | Chicago | 2 | 2016 | 57 | 0.150 |
Why?
| | Eosinophilia | 1 | 2020 | 204 | 0.140 |
Why?
| | Anaphylaxis | 1 | 2018 | 99 | 0.140 |
Why?
| | Neovascularization, Pathologic | 2 | 2009 | 292 | 0.130 |
Why?
| | Janus Kinase 2 | 2 | 2015 | 31 | 0.130 |
Why?
| | Risk Factors | 4 | 2015 | 9779 | 0.130 |
Why?
| | Neoplasm Metastasis | 2 | 2009 | 609 | 0.130 |
Why?
| | Philadelphia Chromosome | 1 | 2016 | 18 | 0.130 |
Why?
| | Vitamin B 12 Deficiency | 1 | 2016 | 78 | 0.120 |
Why?
| | Vitamin B 12 | 1 | 2016 | 121 | 0.120 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2016 | 58 | 0.120 |
Why?
| | Fusion Proteins, bcr-abl | 1 | 2015 | 69 | 0.120 |
Why?
| | Thienamycins | 1 | 2015 | 5 | 0.120 |
Why?
| | Inactivation, Metabolic | 1 | 2015 | 11 | 0.120 |
Why?
| | Piperacillin | 1 | 2015 | 8 | 0.120 |
Why?
| | Anemia, Hemolytic | 1 | 2015 | 16 | 0.120 |
Why?
| | Age Factors | 4 | 2015 | 3150 | 0.120 |
Why?
| | Vitamin K | 1 | 2015 | 41 | 0.120 |
Why?
| | Venous Thromboembolism | 1 | 2018 | 287 | 0.110 |
Why?
| | False Positive Reactions | 1 | 2014 | 114 | 0.110 |
Why?
| | Cell Movement | 2 | 2009 | 942 | 0.110 |
Why?
| | Hemostasis | 1 | 2014 | 80 | 0.110 |
Why?
| | Biomarkers | 2 | 2016 | 3968 | 0.110 |
Why?
| | Signal Transduction | 4 | 2016 | 4916 | 0.110 |
Why?
| | Drug Hypersensitivity | 1 | 2015 | 81 | 0.110 |
Why?
| | Bone Marrow Neoplasms | 1 | 2013 | 3 | 0.110 |
Why?
| | Patient Care Team | 1 | 2018 | 600 | 0.110 |
Why?
| | Blood Transfusion | 1 | 2016 | 298 | 0.110 |
Why?
| | Drug Monitoring | 1 | 2015 | 214 | 0.100 |
Why?
| | Pyrazoles | 2 | 2016 | 403 | 0.100 |
Why?
| | Chi-Square Distribution | 1 | 2014 | 515 | 0.100 |
Why?
| | Academic Medical Centers | 1 | 2016 | 478 | 0.100 |
Why?
| | Thrombocytosis | 1 | 2012 | 6 | 0.100 |
Why?
| | Leukocytosis | 1 | 2012 | 31 | 0.100 |
Why?
| | Interferon-beta | 1 | 2013 | 89 | 0.100 |
Why?
| | Pseudomonas Infections | 1 | 2015 | 222 | 0.100 |
Why?
| | Liver Transplantation | 1 | 2020 | 833 | 0.100 |
Why?
| | Receptor, Interferon alpha-beta | 1 | 2012 | 33 | 0.100 |
Why?
| | Administration, Oral | 1 | 2015 | 783 | 0.100 |
Why?
| | Predictive Value of Tests | 2 | 2015 | 1950 | 0.100 |
Why?
| | Antibodies | 1 | 2014 | 398 | 0.100 |
Why?
| | Adult | 9 | 2022 | 35505 | 0.100 |
Why?
| | Annexin A2 | 2 | 2009 | 10 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 850 | 0.100 |
Why?
| | Prognosis | 3 | 2016 | 3772 | 0.100 |
Why?
| | Nitriles | 1 | 2012 | 169 | 0.090 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2015 | 1327 | 0.090 |
Why?
| | RNA-Binding Proteins | 1 | 2014 | 388 | 0.090 |
Why?
| | Respiratory Tract Infections | 1 | 2015 | 376 | 0.090 |
Why?
| | Phosphoproteins | 1 | 2012 | 333 | 0.080 |
Why?
| | Apoptosis | 2 | 2009 | 2488 | 0.080 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2016 | 596 | 0.080 |
Why?
| | Carrier Proteins | 1 | 2014 | 740 | 0.080 |
Why?
| | Nuclear Proteins | 1 | 2014 | 659 | 0.080 |
Why?
| | Leukemia, Promyelocytic, Acute | 1 | 2009 | 12 | 0.080 |
Why?
| | Cryoglobulins | 1 | 2009 | 6 | 0.080 |
Why?
| | Carboxypeptidase B2 | 1 | 2009 | 3 | 0.080 |
Why?
| | Pyrimidines | 1 | 2012 | 458 | 0.080 |
Why?
| | Plasminogen Inactivators | 1 | 2009 | 3 | 0.080 |
Why?
| | Receptors, Peptide | 1 | 2009 | 17 | 0.080 |
Why?
| | Anemia, Hemolytic, Autoimmune | 1 | 2009 | 15 | 0.080 |
Why?
| | Blood Group Antigens | 1 | 2009 | 15 | 0.080 |
Why?
| | Cerebral Infarction | 1 | 2009 | 41 | 0.080 |
Why?
| | Disease Progression | 3 | 2015 | 2628 | 0.080 |
Why?
| | Factor VII | 1 | 2008 | 22 | 0.080 |
Why?
| | Edetic Acid | 1 | 2008 | 49 | 0.080 |
Why?
| | Nerve Tissue Proteins | 1 | 2012 | 569 | 0.080 |
Why?
| | von Willebrand Factor | 1 | 2008 | 71 | 0.070 |
Why?
| | Multiple Organ Failure | 1 | 2009 | 123 | 0.070 |
Why?
| | Factor VIII | 1 | 2008 | 87 | 0.070 |
Why?
| | Time Factors | 2 | 2018 | 6530 | 0.070 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2020 | 200 | 0.070 |
Why?
| | Immunoglobulin M | 1 | 2009 | 276 | 0.070 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1416 | 0.070 |
Why?
| | Practice Patterns, Physicians' | 1 | 2016 | 1257 | 0.070 |
Why?
| | Neoplasm Invasiveness | 1 | 2009 | 481 | 0.070 |
Why?
| | Animals | 7 | 2016 | 35334 | 0.070 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2009 | 373 | 0.070 |
Why?
| | Cell Division | 1 | 2009 | 787 | 0.070 |
Why?
| | Blood Coagulation Disorders | 1 | 2009 | 167 | 0.070 |
Why?
| | Female | 9 | 2023 | 68650 | 0.070 |
Why?
| | Membrane Proteins | 1 | 2012 | 1118 | 0.060 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2023 | 577 | 0.060 |
Why?
| | Intestines | 1 | 2009 | 350 | 0.060 |
Why?
| | Ischemia | 1 | 2009 | 405 | 0.060 |
Why?
| | Retrospective Studies | 4 | 2016 | 14532 | 0.060 |
Why?
| | Cytokines | 2 | 2014 | 2018 | 0.060 |
Why?
| | Cystic Fibrosis | 1 | 2015 | 1067 | 0.060 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1708 | 0.060 |
Why?
| | Janus Kinases | 2 | 2016 | 12 | 0.060 |
Why?
| | Societies, Medical | 2 | 2018 | 757 | 0.060 |
Why?
| | Erythroid Cells | 2 | 2015 | 9 | 0.060 |
Why?
| | Aging | 1 | 2014 | 1770 | 0.060 |
Why?
| | Mice | 5 | 2014 | 16973 | 0.060 |
Why?
| | Molecular Targeted Therapy | 2 | 2018 | 391 | 0.060 |
Why?
| | Immunosuppressive Agents | 1 | 2009 | 858 | 0.050 |
Why?
| | Aged | 4 | 2016 | 22063 | 0.050 |
Why?
| | Hepatitis B virus | 1 | 2003 | 36 | 0.050 |
Why?
| | Treatment Outcome | 4 | 2018 | 10232 | 0.050 |
Why?
| | Virus Integration | 1 | 2003 | 69 | 0.050 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 2 | 2015 | 277 | 0.050 |
Why?
| | Papillomaviridae | 1 | 2003 | 112 | 0.050 |
Why?
| | Middle Aged | 5 | 2016 | 31087 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2009 | 1366 | 0.050 |
Why?
| | Survival Analysis | 2 | 2018 | 1270 | 0.050 |
Why?
| | Male | 7 | 2020 | 63586 | 0.040 |
Why?
| | Autoantibodies | 1 | 2009 | 1468 | 0.040 |
Why?
| | Combined Modality Therapy | 2 | 2017 | 1201 | 0.040 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2003 | 230 | 0.040 |
Why?
| | Hematopoietic Stem Cells | 2 | 2014 | 382 | 0.040 |
Why?
| | Phosphorylation | 2 | 2014 | 1714 | 0.040 |
Why?
| | mRNA Cleavage and Polyadenylation Factors | 1 | 2018 | 27 | 0.040 |
Why?
| | Histamine Antagonists | 1 | 2018 | 20 | 0.040 |
Why?
| | Fetus | 1 | 2023 | 780 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2018 | 62 | 0.040 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2018 | 39 | 0.040 |
Why?
| | Fibroblasts | 2 | 2014 | 943 | 0.040 |
Why?
| | Liver Neoplasms | 1 | 2003 | 635 | 0.040 |
Why?
| | Prevalence | 2 | 2015 | 2561 | 0.030 |
Why?
| | Mast Cells | 1 | 2018 | 142 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2018 | 402 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2018 | 310 | 0.030 |
Why?
| | Bone Marrow | 1 | 2018 | 272 | 0.030 |
Why?
| | Cell Line, Tumor | 2 | 2015 | 3181 | 0.030 |
Why?
| | Receptors, Thrombopoietin | 1 | 2016 | 5 | 0.030 |
Why?
| | Thrombopoietin | 1 | 2016 | 5 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2015 | 4087 | 0.030 |
Why?
| | Benzoates | 1 | 2016 | 41 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 763 | 0.030 |
Why?
| | Hydrazines | 1 | 2016 | 34 | 0.030 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2016 | 91 | 0.030 |
Why?
| | Receptors, Fc | 1 | 2016 | 52 | 0.030 |
Why?
| | General Practice | 1 | 2016 | 28 | 0.030 |
Why?
| | Platelet Count | 1 | 2015 | 82 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 1037 | 0.030 |
Why?
| | Autophagy-Related Protein-1 Homolog | 1 | 2015 | 7 | 0.030 |
Why?
| | Azacitidine | 1 | 2016 | 137 | 0.030 |
Why?
| | Immunologic Tests | 1 | 2015 | 16 | 0.030 |
Why?
| | Biopsy | 1 | 2018 | 1087 | 0.030 |
Why?
| | Interferon Regulatory Factors | 1 | 2015 | 33 | 0.030 |
Why?
| | Patient Selection | 1 | 2018 | 659 | 0.030 |
Why?
| | Response Elements | 1 | 2015 | 89 | 0.030 |
Why?
| | Nuclear Cap-Binding Protein Complex | 1 | 2014 | 1 | 0.030 |
Why?
| | Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2014 | 12 | 0.030 |
Why?
| | Ubiquitins | 1 | 2014 | 36 | 0.030 |
Why?
| | Interferons | 1 | 2016 | 189 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2016 | 7052 | 0.030 |
Why?
| | Guanosine | 1 | 2014 | 41 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 2013 | 0.030 |
Why?
| | Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2014 | 28 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2016 | 557 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 117 | 0.030 |
Why?
| | Risk | 1 | 2016 | 857 | 0.030 |
Why?
| | Medication Adherence | 1 | 2018 | 560 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 2016 | 650 | 0.030 |
Why?
| | Mutation, Missense | 1 | 2015 | 315 | 0.030 |
Why?
| | Microbial Sensitivity Tests | 1 | 2015 | 349 | 0.030 |
Why?
| | Eukaryotic Initiation Factor-4E | 1 | 2013 | 27 | 0.030 |
Why?
| | Cell Line, Transformed | 1 | 2013 | 139 | 0.030 |
Why?
| | U937 Cells | 1 | 2012 | 24 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2014 | 315 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 1368 | 0.030 |
Why?
| | Aspirin | 1 | 2015 | 378 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1491 | 0.020 |
Why?
| | Hospitalists | 1 | 2016 | 232 | 0.020 |
Why?
| | Embryo, Mammalian | 1 | 2012 | 224 | 0.020 |
Why?
| | Patient Outcome Assessment | 1 | 2013 | 126 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2016 | 617 | 0.020 |
Why?
| | Logistic Models | 1 | 2016 | 1983 | 0.020 |
Why?
| | Pregnancy | 1 | 2023 | 6412 | 0.020 |
Why?
| | Leukemia | 1 | 2013 | 230 | 0.020 |
Why?
| | Vascular Diseases | 1 | 2013 | 240 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2016 | 885 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2012 | 398 | 0.020 |
Why?
| | Splanchnic Circulation | 1 | 2009 | 10 | 0.020 |
Why?
| | Infarction | 1 | 2009 | 9 | 0.020 |
Why?
| | Plasmapheresis | 1 | 2009 | 22 | 0.020 |
Why?
| | Blood Specimen Collection | 1 | 2008 | 35 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2009 | 184 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 86 | 0.020 |
Why?
| | Giant Cell Arteritis | 1 | 2009 | 49 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3255 | 0.020 |
Why?
| | Immunoassay | 1 | 2008 | 108 | 0.020 |
Why?
| | Tretinoin | 1 | 2009 | 121 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2009 | 300 | 0.020 |
Why?
| | Rituximab | 1 | 2009 | 164 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1559 | 0.020 |
Why?
| | Plasma | 1 | 2008 | 206 | 0.020 |
Why?
| | Spleen | 1 | 2009 | 508 | 0.020 |
Why?
| | Hospitalization | 1 | 2016 | 2076 | 0.020 |
Why?
| | Internship and Residency | 1 | 2016 | 1049 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2012 | 2887 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2013 | 1895 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 5078 | 0.010 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2003 | 282 | 0.010 |
Why?
| | United States | 1 | 2018 | 13865 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2003 | 931 | 0.010 |
Why?
| | Kidney | 1 | 2009 | 1382 | 0.010 |
Why?
| | Liver | 1 | 2009 | 1836 | 0.010 |
Why?
| | Base Sequence | 1 | 2003 | 2138 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2003 | 2827 | 0.010 |
Why?
| | Adolescent | 1 | 2015 | 20409 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2003 | 1438 | 0.010 |
Why?
|
|
Mcmahon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|